0
     

Report Added
Report already added
Pruritus Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Pruritus Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pruritus - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Pruritus (Dermatology) pipeline landscape.

Pruritus, or itch, is defined as an unpleasant sensation that provokes the desire to scratch. Pruritus is caused by cancer, cancer treatments, infection, dry skin and reaction to a drug. Symptoms include redness, bumps, spots or blisters, dry, cracked skin and leathery or scaly texture to the skin. Risk factors include heat, allergic, asthma, hay fever, hives and eczema. Treatment includes corticosteroids, antihistamines and antidepressants.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Pruritus - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Pruritus (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Pruritus (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Pruritus and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 3, 5, 11, 11, 14, 3 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 3 molecules, respectively.

Pruritus (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Pruritus (Dermatology).
- The pipeline guide reviews pipeline therapeutics for Pruritus (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Pruritus (Dermatology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Pruritus (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Pruritus (Dermatology)

Reasons to Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Pruritus (Dermatology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Pruritus (Dermatology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Pruritus - Overview
Pruritus - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Pruritus - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Pruritus - Companies Involved in Therapeutics Development
9 Meters Biopharma Inc
AfaSci Inc
Akaal Pharma Pty Ltd
Albireo Pharma Inc
Amgen Inc
AntalGenics SL
AOBiome LLC
Asana BioSciences LLC
Avior Bio Inc
BioArdis LLC
Biomimetix JV LLC
Cara Therapeutics Inc
Chugai Pharmaceutical Co Ltd
Clexio Biosciences Ltd
DermaXon LLC
DongKoo Bio & Pharma Co Ltd
ELORAC Inc
Escient Pharmaceuticals Inc
Evommune Inc
Genu Pharma Co Ltd
GlaxoSmithKline Plc
Jiangsu Hengrui Medicine Co Ltd
Kiniksa Pharmaceuticals Ltd
Kissei Pharmaceutical Co Ltd
Lumosa Therapeutics Co Ltd
MC2 Therapeutics AS
Mirum Pharmaceuticals Inc
Neurim Pharmaceuticals Ltd
Patagonia Pharmaceuticals LLC
Peptide Logic LLC
Pfizer Inc
RaQualia Pharma Inc
Regeneron Pharmaceuticals Inc
Saniona AB
Sanwa Kagaku Kenkyusho Co Ltd
Shanton Pharma Co Ltd
Sichuan Haisco Pharmaceutical Co Ltd
Sienna Biopharmaceuticals Inc
Sunny Pharmtech Inc
Suzhou Connect Biopharmaceuticals Ltd
Teikoku Pharma USA Inc
Tioga Pharmaceuticals Inc
Titan Pharmaceuticals Inc
Toray Industries Inc
Trevi Therapeutics Inc
Vivozon Inc
YIRUI Pharmaceutical Technology Co Ltd
Pruritus - Drug Profiles
abrocitinib - Drug Profile
Product Description
Mechanism Of Action
History of Events
AG-1529 - Drug Profile
Product Description
Mechanism Of Action
AKP-11 - Drug Profile
Product Description
Mechanism Of Action
History of Events
AM-6120 - Drug Profile
Product Description
Mechanism Of Action
AMG-8379 - Drug Profile
Product Description
Mechanism Of Action
asimadoline - Drug Profile
Product Description
Mechanism Of Action
History of Events
ASN-008 - Drug Profile
Product Description
Mechanism Of Action
History of Events
ASN-009 - Drug Profile
Product Description
Mechanism Of Action
AV-104 - Drug Profile
Product Description
Mechanism Of Action
History of Events
B-244 - Drug Profile
Product Description
Mechanism Of Action
History of Events
bepotastine SR - Drug Profile
Product Description
Mechanism Of Action
BMX-010 - Drug Profile
Product Description
Mechanism Of Action
History of Events
CBP-174 - Drug Profile
Product Description
Mechanism Of Action
History of Events
detomidine - Drug Profile
Product Description
Mechanism Of Action
difelikefalin - Drug Profile
Product Description
Mechanism Of Action
History of Events
DKB-19003 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Drugs to Block Cav3 and Nav for Pruritus - Drug Profile
Product Description
Mechanism Of Action
dupilumab - Drug Profile
Product Description
Mechanism Of Action
History of Events
DX-412 - Drug Profile
Product Description
Mechanism Of Action
History of Events
EP-547 - Drug Profile
Product Description
Mechanism Of Action
History of Events
EVO-103 - Drug Profile
Product Description
Mechanism Of Action
HPI-1201 - Drug Profile
Product Description
Mechanism Of Action
History of Events
HSK-21542 - Drug Profile
Product Description
Mechanism Of Action
KNV-0969 - Drug Profile
Product Description
Mechanism Of Action
linerixibat - Drug Profile
Product Description
Mechanism Of Action
History of Events
LT-5001 - Drug Profile
Product Description
Mechanism Of Action
History of Events
MC-225 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Monoclonal Antibody Conjugate to Agonize Kappa Opioid Receptor for Dermatosis, Osteoarthritis Pain and Uremic Pruritus - Drug Profile
Product Description
Mechanism Of Action
History of Events
MRGPRX2 Antagonist - Drug Profile
Product Description
Mechanism Of Action
nalbuphine hydrochloride ER - Drug Profile
Product Description
Mechanism Of Action
History of Events
nalfurafine hydrochloride - Drug Profile
Product Description
Mechanism Of Action
History of Events
naloxone hydrochloride - Drug Profile
Product Description
Mechanism Of Action
History of Events
nemolizumab - Drug Profile
Product Description
Mechanism Of Action
History of Events
NeuP-12 - Drug Profile
Product Description
Mechanism Of Action
odevixibat - Drug Profile
Product Description
Mechanism Of Action
History of Events
opiranserin - Drug Profile
Product Description
Mechanism Of Action
PATN-02 - Drug Profile
Product Description
Mechanism Of Action
pegcantratinib - Drug Profile
Product Description
Mechanism Of Action
History of Events
Peptides to Target TRPV1 for Pain and Pruritus - Drug Profile
Product Description
Mechanism Of Action
phenylbutyrate - Drug Profile
Product Description
Mechanism Of Action
PR-38 - Drug Profile
Product Description
Mechanism Of Action
RDD-1609 - Drug Profile
Product Description
Mechanism Of Action
SAN-711 - Drug Profile
Product Description
Mechanism Of Action
History of Events
SAP-002 - Drug Profile
Product Description
Mechanism Of Action
SHR-0410 - Drug Profile
Product Description
Mechanism Of Action
History of Events
SK-1405 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecule to Agonize KOR1 for Pruritus - Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Block Nav1.8 Sodium Channel for Pain And Pruritis - Drug Profile
Product Description
Mechanism Of Action
History of Events
TPU-010 - Drug Profile
Product Description
Mechanism Of Action
vixarelimab - Drug Profile
Product Description
Mechanism Of Action
History of Events
volixibat potassium - Drug Profile
Product Description
Mechanism Of Action
History of Events
YR-007 - Drug Profile
Product Description
Mechanism Of Action
Pruritus - Dormant Projects
Pruritus - Discontinued Products
Pruritus - Product Development Milestones
Featured News & Press Releases
Mar 28, 2022: Cara Therapeutics announces Oral KORSUVA (difelikefalin) improves itch and inflammatory biomarkers in atopic dermatitis patients with moderate-to-severe pruritus
Mar 08, 2022: Cara Therapeutics announces oral KORSUVA (difelikefalin) data selected for late-breaking presentation at 2022 American Academy of Dermatology Annual Meeting
Feb 25, 2022: Kapruvia receives positive CHMP opinion for the treatment of moderate-to-severe pruritus in hemodialysis patients
Feb 22, 2022: AOBiome Therapeutics' topical biotherapeutic B244 demonstrated positive Phase 2b results from its 547 patient trial for both Pruritus (Itch) and appearance in its 547 patient Phase 2b trial of Atopic Dermatitis (Eczema)
Feb 02, 2022: Trevi concludes enrolment of Phase IIb/III itch trial in prurigo nodularis
Jan 10, 2022: Cara Therapeutics announces Difelikefalin (KORSUVA) Injection achieves positive topline results in Phase 3 clinical study in Japan for the treatment of pruritus in hemodialysis patients
Jan 10, 2022: Cara Therapeutics announces Difelikefalin (KORSUVA) Injection achieves positive topline results in Phase 3 clinical study in Japan for the treatment of pruritus in hemodialysis patients
Jan 05, 2022: Enteris BioPharma highlights 2021 achievements and 2022 Outlook
Jan 05, 2022: Albireo increases 2021 Bylvay (odevixibat) sales guidance
Dec 20, 2021: Cara Therapeutics announces CMS grants TDAPA to KORSUVA (difelikefalin) injection
Dec 13, 2021: Albireo presenting new Bylvay (odevixibat) Data at NASPGHAN 2021
Nov 16, 2021: AOBiome achieves landmark recruitment goal in largest clinical trial ever powered by a live topical biotherapeutic
Nov 15, 2021: Trevi Therapeutics to present at 5th Annual Dermatology Drug Development Summit for Inflammatory Skin Diseases
Nov 12, 2021: Albireo announces new phase 3 data for Bylvay (odevixibat) in PFIC and first reveal of new next generation bile acid modulator data at AASLD The Liver Meeting 2021
Nov 05, 2021: Titan announces upcoming TP-2021 Implant data presentation at Neuroscience 2021
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Pruritus, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Companies, 2022 (Contd..1)
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Companies, 2022 (Contd..2)
Products under Development by Companies, 2022 (Contd..3)
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Target, 2022 (Contd..1)
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Mechanism of Action, 2022 (Contd..1)
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Pruritus - Pipeline by 9 Meters Biopharma Inc, 2022
Pruritus - Pipeline by AfaSci Inc, 2022
Pruritus - Pipeline by Akaal Pharma Pty Ltd, 2022
Pruritus - Pipeline by Albireo Pharma Inc, 2022
Pruritus - Pipeline by Amgen Inc, 2022
Pruritus - Pipeline by AntalGenics SL, 2022
Pruritus - Pipeline by AOBiome LLC, 2022
Pruritus - Pipeline by Asana BioSciences LLC, 2022
Pruritus - Pipeline by Avior Bio Inc, 2022
Pruritus - Pipeline by BioArdis LLC, 2022
Pruritus - Pipeline by Biomimetix JV LLC, 2022
Pruritus - Pipeline by Cara Therapeutics Inc, 2022
Pruritus - Pipeline by Chugai Pharmaceutical Co Ltd, 2022
Pruritus - Pipeline by Clexio Biosciences Ltd, 2022
Pruritus - Pipeline by DermaXon LLC, 2022
Pruritus - Pipeline by DongKoo Bio & Pharma Co Ltd, 2022
Pruritus - Pipeline by ELORAC Inc, 2022
Pruritus - Pipeline by Escient Pharmaceuticals Inc, 2022
Pruritus - Pipeline by Evommune Inc, 2022
Pruritus - Pipeline by Genu Pharma Co Ltd, 2022
Pruritus - Pipeline by GlaxoSmithKline Plc, 2022
Pruritus - Pipeline by Jiangsu Hengrui Medicine Co Ltd, 2022
Pruritus - Pipeline by Kiniksa Pharmaceuticals Ltd, 2022
Pruritus - Pipeline by Kissei Pharmaceutical Co Ltd, 2022
Pruritus - Pipeline by Lumosa Therapeutics Co Ltd, 2022
Pruritus - Pipeline by MC2 Therapeutics AS, 2022
Pruritus - Pipeline by Mirum Pharmaceuticals Inc, 2022
Pruritus - Pipeline by Neurim Pharmaceuticals Ltd, 2022
Pruritus - Pipeline by Patagonia Pharmaceuticals LLC, 2022
Pruritus - Pipeline by Peptide Logic LLC, 2022
Pruritus - Pipeline by Pfizer Inc, 2022
Pruritus - Pipeline by RaQualia Pharma Inc, 2022
Pruritus - Pipeline by Regeneron Pharmaceuticals Inc, 2022
Pruritus - Pipeline by Saniona AB, 2022
Pruritus - Pipeline by Sanwa Kagaku Kenkyusho Co Ltd, 2022
Pruritus - Pipeline by Shanton Pharma Co Ltd, 2022
Pruritus - Pipeline by Sichuan Haisco Pharmaceutical Co Ltd, 2022
Pruritus - Pipeline by Sienna Biopharmaceuticals Inc, 2022
Pruritus - Pipeline by Sunny Pharmtech Inc, 2022
Pruritus - Pipeline by Suzhou Connect Biopharmaceuticals Ltd, 2022
Pruritus - Pipeline by Teikoku Pharma USA Inc, 2022
Pruritus - Pipeline by Tioga Pharmaceuticals Inc, 2022
Pruritus - Pipeline by Titan Pharmaceuticals Inc, 2022
Pruritus - Pipeline by Toray Industries Inc, 2022
Pruritus - Pipeline by Trevi Therapeutics Inc, 2022
Pruritus - Pipeline by Vivozon Inc, 2022
Pruritus - Pipeline by YIRUI Pharmaceutical Technology Co Ltd, 2022
Pruritus - Dormant Projects, 2022
Pruritus - Dormant Projects, 2022 (Contd..1)
Pruritus - Discontinued Products, 2022

List of Figures
Number of Products under Development for Pruritus, 2022
Number of Products under Development by Companies, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022

Report Title: Pruritus Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update


Your Details
Valid Invalid number

SELECT A FORMAT

ADD TO CART BUY NOW